TSW
FENC icon

Thompson Siegel & Walmsley’s Fennec Pharmaceuticals FENC Stock Holding History

Thompson Siegel & Walmsley’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Buy
+57,226
New +$442K 0.01% 384

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Thompson Siegel & Walmsley's FENC Position: Q1 2026 in Review

Thompson Siegel & Walmsley opened a new position in Fennec Pharmaceuticals (FENC) in Q1 2026: 57,226 shares worth $352K. The stake represents 0.01% of the portfolio and ranks #384 among its holdings.

90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Thompson Siegel & Walmsley held 57,226 shares of Fennec Pharmaceuticals worth $352K as of Q1 2026.
  • Fennec Pharmaceuticals was a new Thompson Siegel & Walmsley position in Q1 2026.
  • Fennec Pharmaceuticals made up 0.01% of Thompson Siegel & Walmsley's portfolio in Q1 2026, its #384 holding.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2026, filed 11 May 2026.